Title: Randomized Trial of Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer1
Principal Investigator: Jennifer Temel, MD, Massachusetts General Hospital
Description: For this randomized study, researchers are evaluating whether early integrated palliative care yields superior quality of life outcomes to stepped palliative care among patients with advanced small-cell lung cancer, non–small cell lung cancer, or mesothelioma being treated with non-curative intent.
As advanced lung cancer can drastically affect patient quality of life, a patient’s palliative care schedule can be critical for improving outcomes. Participants in this study will be randomly assigned to receive early integrated palliative care, in which patients will meet with a clinician every 4 weeks post-enrollment, or stepped palliative care, in which patients will meet will a clinician within 4 weeks of enrollment and, in the case of quality of life deterioration, meet with a clinician every 4 weeks thereafter.
The primary goal is assessing whether stepped palliative care is non-inferior to early integrated palliative care for quality of life outcomes.
For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT03337399.
Status: This study is open and recruiting patients as of March 28, 2018.
This study is sponsored by Massachusetts General Hospital in collaboration with the National Cancer Institute.
- Clinicaltrials.gov. Stepped palliative care versus early integrated palliative care in patients with advanced lung cancer (STEP PC). NCT03337399. https://clinicaltrials.gov/ct2/show/NCT03337399. Accessed March 28, 2018.